Go to Top

Blog Archives

ADMA Biologics, Inc. (ADMA): Offering is Imminent

ADMA Biologics, Inc. (ADMA) shares price almost doubled since company announced that the FDA approved its Asceniv, intravenous immunoglobulin product for the treatment of primary humoral immunodeficiency disease (PIDD), in adults and adolescents ages from 12 to 17. PIDD is a collective term for numerous diseases that occur due to defects in the body’s immune …Read More

Proteostasis Therapeutics (PTI): Market Overreaction

Shares of Proteostasis Therapeutics Inc. (PTI) slightly recovered during today’s trading after huge drop on Monday’s session when company announced results from a phase 1 study of its cystic fibrosis (CF) treatment. BOSTON, March 25, 2019 /PRNewswire/ — Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies …Read More

Sientra (NASDAQ: SIEN) : DD and More

A few excerpts: PennyStockHaven: From Sientra’s (SIEN) 8-K filing from October 30th, 2015: We continue to be well funded with a cash and cash equivalents balance of $148.9 million as of September 30, 2015. Earlier this week we paid in full our term loans totaling $24.5 million, and as a result the company has no outstanding …Read More

SANUWAVE (SNWV): U.S. Patent to Sterilize Blood Using SNWV’s Shock Wave Technology

SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled “Method and Devices for Cleaning and Sterilization with Shock Waves.” The claims of the patent (patent number 8,343,420) relate to a new method that sterilizes blood by applying external shock waves to destroy blood pathogens contained in bags, …Read More

BioCryst Pharmaceuticals (BCRX): Update Regarding Peramivir

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst announced that it received a preliminary comment letter from the FDA that outlines a pathway by which BioCryst could file a New Drug Application (NDA) seeking regulatory approval of its drug candidate intravenous …Read More

Cell Therapeutics, Inc.(CTIC): $15MM Loan Financing Agreement

Cell Therapeutics, Inc.  (CTIC) announced that it has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a senior secured term loan of up to $15 million. The first $10 million of the term loan was funded on March 27, 2013, and the remaining $5 million is available at the …Read More

AntriaBio (ANTB): An Opportunity

Novo Nordisk – the world’s largest insulin producer – and major diabetes drug manufacturers – could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment. Over $100,000,000 has been invested in developing this super-drug that threatens to make products like Sanofi’s $6 …Read More

Oncolytics Biotech (ONCY): Positive REOLSYIN Clinical Trial Data from Phase 2 Study

Oncolytics Biotech Inc. (NASDAQ: ONCY) is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently in late stage (Phase III) clinical testing in head and neck cancers. REOLYSIN® has been utilized in nearly thirty clinical trials including translational, Phase I, …Read More

Imprimis Pharmaceuticals (IMMY): Pricing of Public Offering at $5.25 per Share

Imprimis Pharmaceuticals, Inc. (IMMY) is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. Through an exclusive strategic relationship with the largest compounding pharmacy organization in North America, Imprimis expects to use its proprietary Accudel drug delivery technology, coupled with licensed technologies, and proprietary formulations and market data, to identify pharmaceutical …Read More